Soligenix - U.S. Commercialization of SGX301 in the Treatment of Cutaneous T-Cell Lymphoma
15 Pogledi
administrator
08/09/23
Soligenix Investor Webcast Event held on Tuesday, January 26, 2021 from 2:30-4:00 PM Eastern Standard Time (EST) regarding United States (U.S) commercial planning for SGX301 in the treatment of Cutaneous T-Cell Lymphoma (CTCL).
Prikaži više
Komentari na Facebooku
Nema komentara